General
Starting a Biotech? Move to Maryland
Let’s face it: current conditions don’t favor a startup company of any kind, and especially not a biotech.
Though the current economic crisis seems to be centered around mostly finance and real estate, the stock market crunch borne from the climate is obviously not kind to angel investors and venture capital firms, which in turn make [...]
Loosing Sleep over Economic Crisis
It seems almost every conversation these days starts with people lamenting over the state of their stock portfolios. No matter what you’ve invested in, no matter how secure you believe your investments to be, you get weak in the knees when going to check on the current state of your 401k, or 503b, or 529 [...]
Latest Tactics to Stifle Generic Competition
In the last half of this decade, it is estimated that $100 billion worth of brand name drugs have lost (or will lose) patent exclusivity. Each year, generic drugs take more and more of the market share from brand-name drug manufacturers. In fact, the percentage of drug prescriptions dispensed for generics increased from 47% to [...]
“Approvable” Removed from the FDA Lexicon
One of my first assignments in the pharmaceutical industry was as project manager for a product registration tracking system at one of the big drug companies. The system held the registration status of all of the company’s products worldwide – whether the product was submitted for approval in a given country, approved for marketing, [...]
ROXRO Pharma: How to Score Big as the (Really) Little Guy
Last week I attended a Pharmaceutical Executive web conference called “A Better Way to Conduct Alliance Management”. The conference was somewhat interesting, but in reality, it was more of an hour long advertisement for Intralinks, the conference sponsor. However, one of the speakers at the conference intrigued me: Gayle Mills, Executive Vice President of Business [...]
Loading ...